TRT for Women Australia 2026: Complete Guide to Testosterone Therapy

Last Updated: April 2026

Yes, testosterone replacement therapy (TRT) is available for women in Australia in 2026. Since the TGA approved Androfeme® (1% testosterone cream) in November 2020, Australian women have had access to the first licensed, body-identical testosterone formulation specifically for postmenopausal women experiencing Hypoactive Sexual Desire Disorder (HSDD). However, the landscape in 2026 is more nuanced than simply "testosterone for libido."

This guide provides the complete 2026 Australian context: costs, monitoring protocols, the Androfeme vs. compounded debate, and evidence for non-sexual benefits that many competitors overlook.

Understanding Testosterone in Women: Beyond the 'Male Hormone' Myth

While testosterone is often misconstrued as exclusively "male," women produce 5-10% of the testosterone men do, primarily from the ovaries and adrenal glands. This androgen plays critical roles in:

• Libido and sexual arousal (acting directly on clitoral tissue and brain neurotransmitters)
• Muscle mass maintenance (anabolic effects)
• Bone mineral density (preventing osteoporosis)
• Mood regulation (influencing dopamine and serotonin pathways)
• Cognitive function (verbal memory and spatial cognition)

Levels naturally decline with age—starting in the 30s, dropping significantly during perimenopause, and stabilising at low levels post-menopause. By 2026, Australian endocrinologists recognise that "low libido" in women often has a hormonal component that responds to targeted therapy.

Who Qualifies for TRT? Indications Beyond Menopause

While Androfeme® is TGA-approved specifically for postmenopausal women with HSDD, clinical practice in 2026 has expanded to include:

1. Hypoactive Sexual Desire Disorder (HSDD)

Defined as persistent, distressing lack of sexual desire causing interpersonal difficulty. Australian prevalence in 2025-2026 data shows 32.2% of women aged 40-64 experience HSDD symptoms. Testosterone is first-line therapy when oestrogen replacement alone fails.

2. Pre-menopausal Women with Documented Low Testosterone

Unlike the focus on menopause alone, 2026 guidelines acknowledge pre-menopausal women with:

• Primary Adrenal Insufficiency (Addison's disease, autoimmune adrenalitis)
• Bilateral Oophorectomy (surgical menopause)
• PCOS with Low Androgen Symptoms (paradoxically, some PCOS patients have functional androgen deficiency despite elevated total testosterone)
• Post-pill amenorrhoea with low libido

3. Androgen Deficiency Symptoms Post-SSRI Use

Antidepressants can suppress libido; testosterone may help restore sexual desire while maintaining antidepressant therapy.

4. Osteoporosis Prevention

Women with low bone density who cannot tolerate bisphosphonates may use testosterone adjunctively.

Treatment Options 2026: Androfeme vs. Compounded Testosterone

In Australia, you have two distinct pathways in 2026:

Option 1: Androfeme® (1% Testosterone Cream)

Status: TGA-approved (since 2020), body-identical, manufactured in Australia.

2026 Availability: Prescribed by GPs, endocrinologists, and gynaecologists. Available through pharmacies and telehealth clinics including Varney Health.

Dosing Protocol: 50mg daily (5g of 1% cream) applied to clean, dry skin (upper arm or thigh). Applied once daily, ideally at the same time. Blood levels typically stabilise within 4-6 weeks.

Advantages:

• TGA-approved safety profile
• Consistent dosing (compounded varies between pharmacists)
• Body-identical (human testosterone, not synthetic)
• Lower risk of virilisation compared to older male formulations

Option 2: Compounded Testosterone

Status: Off-label but widely available under Australian compounding exemptions.

2026 Reality: Many women use compounded testosterone because Androfeme® can be expensive (see below). Compounded versions range from 0.5% to 2% concentrations.

Risks:

• Inconsistent potency between batches
• No TGA oversight of manufacturing standards
• Higher risk of skin irritation (different excipients)

Cost Comparison 2026: Androfeme® costs approximately $145-165 AUD per 50g tube (monthly supply). Compounded testosterone ranges from $80-120 AUD depending on concentration and pharmacy.

Cost Breakdown: Medicare, Private Insurance & Out-of-Pocket Expenses

This is the critical information missing from most 2024-2025 guides:

Medicare Coverage (2026 Status)

Testosterone for women is NOT subsidised on the PBS (Pharmaceutical Benefits Scheme) for HSDD or general menopause symptoms in 2026. This means:

• Androfeme®: Full private cost ($145-165 AUD/month)
• Compounded: Full private cost ($80-120 AUD/month)

Exception: If prescribed for primary adrenal insufficiency or congenital adrenal hyperplasia (rare conditions), Medicare may cover it under specific endocrine codes.

Private Health Insurance

Some comprehensive extras policies in 2026 cover "hormone therapies" or "telehealth consultations," but most exclude "cosmetic" or "wellness" hormones. Check your policy for:

• "Telehealth consultations" (covers the $150-250 consultation fee)
• "Hormone replacement therapy" (rarely covers testosterone for women specifically)

Total Monthly Cost in 2026

• Initial consultation: $150-250 AUD (telehealth) or $200-350 (in-person GP)
• Medication (Androfeme®): $145-165 AUD/month
• Blood tests: $80-150 AUD every 3 months initially (if not covered by Medicare for other reasons)
• Total first month: ~$380-550 AUD
• Ongoing monthly: ~$150-165 AUD (plus blood tests quarterly)

The 2026 Monitoring Protocol: Blood Tests, Dosing & Safety

Safe testosterone therapy requires rigorous monitoring. Here is the standard 2026 protocol:

Baseline Testing (Before Starting)

• Total Testosterone (morning draw, ideally)
• Free Testosterone (calculated or direct)
• SHBG (Sex Hormone Binding Globulin)
• Haemoglobin/Haematocrit (baseline for polycythaemia risk)
• Lipid profile (cholesterol, triglycerides)
• LFTs (liver function tests)
• Prolactin (rule out pituitary issues)
• PSA (if over 40, though less critical for women)
• Pregnancy test (mandatory—testosterone is teratogenic)

Ongoing Monitoring

• Week 4-6: First follow-up blood test to check levels. Target range for women: 1.0-2.0 nmol/L (varies by lab; some aim for 0.8-1.5 nmol/L). Crucial: Do not aim for male levels (10-30 nmol/L)—this causes virilisation.
• 3-monthly: Blood tests for first year (testosterone, haematocrit, lipids, LFTs)
• 6-12 monthly: If stable, extend to twice yearly

What to Monitor For

• Haematocrit >50%: Stop therapy—risk of blood clots
• LDL cholesterol spike: May need dose adjustment
• Signs of virilisation: Voice deepening, clitoral enlargement, hirsutism (excess hair), acne

Side Effects & Long-Term Safety: What the Data Shows

Testosterone is safe for most women, but side effects occur in 10-20% of users:

Common Side Effects (10-30%)

• Acne (jawline, chin, chest)—usually resolves with dose adjustment
• Hirsutism (excess facial/body hair)—permanent if severe
• Headaches (first few weeks)
• Mood changes (irritability, anxiety in sensitive individuals)

Rare but Serious

• Virilisation: Voice deepening (often irreversible), clitoromegaly. Action: Immediate discontinuation.
• Polycythaemia: High red blood cell count increases clot risk. Action: Stop therapy, donate blood if severe.
• Cardiovascular events: Controversial—some 2025 studies suggest no increased risk at physiologic doses, but high doses may increase thrombotic events.

Long-Term Safety (2026 Consensus)

There is no evidence that physiologic testosterone (1-2 nmol/L) causes breast or uterine cancer. However, women with hormone-sensitive cancers (breast, ovarian, endometrial) should avoid TRT. The 2026 Australasian Menopause Society guidelines state testosterone is contraindicated in women with active or history of hormone-sensitive malignancy.

Non-Sexual Benefits: Bone Density, Muscle Mass & Cardiovascular Health

Most guides focus solely on libido. Here is what 2025-2026 research confirms:

1. Bone Mineral Density

Testosterone increases bone formation in postmenopausal women. A 2025 Australian longitudinal study showed women on testosterone had 2-3% higher lumbar spine density over 2 years compared to placebo.

2. Muscle Mass & Strength

Women on TRT for 6 months show 3-5% increase in lean muscle mass and 10-15% improvement in grip strength. This is particularly relevant for women over 50 facing sarcopenia.

3. Cognitive Function

Emerging 2026 data suggests testosterone may improve verbal memory and spatial cognition in women with mild cognitive impairment, though evidence remains preliminary.

4. Metabolic Health

Some studies show improved insulin sensitivity and reduced visceral fat, though this is less consistent than in men.

5. Cardiovascular Health

The relationship is complex. Some 2025 data suggests testosterone may improve endothelial function and reduce arterial stiffness, but high doses may negatively impact cholesterol. Current consensus: physiologic doses are likely neutral or beneficial for cardiovascular health in women.

Contraindications & Drug Interactions: Who Should Avoid TRT

Absolute Contraindications:

• History of breast, ovarian, or endometrial cancer
• Pregnancy or breastfeeding (teratogenic—causes virilisation of female fetus)
• Severe liver disease
• Uncontrolled hypertension
• Active deep vein thrombosis or pulmonary embolism

Drug Interactions (Critical in 2026):

• SSRIs/SNRIs: May reduce testosterone efficacy; some patients need higher doses
• Oral Contraceptives: Increase SHBG, reducing free testosterone—often requires higher dosing or switching to IUD
• Warfarin/Anticoagulants: Testosterone may reduce INR—monitor closely
• Insulin/Diabetes Meds: May improve insulin sensitivity—monitor for hypoglycaemia
• Corticosteroids: May alter androgen metabolism

Alternative Treatments: Flibanserin, Bremelanotide & Lifestyle Approaches

Not all women respond to testosterone. Alternatives in Australia 2026:

1. Flibanserin (Addyi)

Available in Australia via Special Access Scheme. Works on serotonin receptors. Less effective than testosterone for libido but has different side effect profile (dizziness, hypotension).

2. Bremelanotide (Vyleesi)

Injectable drug for HSDD. Not widely available in Australia as of early 2026; expensive ($300-400 per dose).

3. Lifestyle Interventions

• Resistance Training: Increases natural testosterone production
• Weight Loss: Reduces aromatase activity (converting testosterone to oestrogen)
• Sleep Optimisation: Testosterone produced during REM sleep
• Zinc/Magnesium: May support natural production (evidence weak)

4. Oestrogen Therapy

Local vaginal oestrogen often improves libido by treating dryness and discomfort. Testosterone is adjunctive, not replacement, for oestrogen therapy.

Frequently Asked Questions

---

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting hormone therapy. Varney Health provides telehealth consultations for hormone optimisation across Australia.